TNF-Blockers: Infection and Cancer Risks

Explore safety/mechanism links for TNF-blocker associated infections and malignancies

Abstract

TNF-blockers demonstrate mechanistically coherent infection risks linked to TNF’s essential role in immune surveillance and host defense. While overall infection risk shows only modest increases (OR 1.18-1.20) that become non-significant when adjusted for exposure time (IRR 1.01), opportunistic infections show consistent 90% increased risk (OR 1.90) and tuberculosis risk increases 3- to 4-fold (OR 3.3-3.5). The mechanism centers on disruption of granuloma formation, explaining why tuberculosis occurs exclusively with monoclonal antibodies that completely neutralize TNF and why 72% of infliximab-associated granulomatous infections occur within 90 days, consistent with reactivation of latent infections rather than increased susceptibility to new pathogens. Agent-specific differences are substantial, with infliximab carrying 3.25-fold greater granulomatous infection risk than etanercept, reflecting mechanistic differences between complete TNF neutralization and partial receptor blockade.

For malignancies, competing biological mechanisms—TNF’s dual roles in suppressing tumors through apoptosis versus promoting cancer through chronic inflammation—generate heterogeneous findings that resolve upon careful examination. Long-term observational studies show no overall increased malignancy risk (OR 0.90-0.95) and no evidence that longer exposure increases risk, while short-term RCT meta-analyses finding elevated risk (OR 3.3) likely reflect detection bias given inadequate latency periods for cancer development. Skin cancers represent the most consistent signal (OR 1.45 for non-melanoma skin cancer), amplified by concomitant methotrexate (RR 1.97). For lymphomas, standardized incidence ratios of 1.8-6.0 in rheumatoid arthritis must be interpreted against 2-fold baseline elevation from systemic inflammation itself, and pooled estimates controlling for this confounding show no significant TNF-blocker effect (OR 1.11). The mechanistic framework suggests that baseline inflammatory disease severity, rather than immunosuppression per se, drives most malignancy risk in these populations.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.

Screening

We screened in sources based on their abstracts that met the following criteria:

• TNF-Blocker Intervention: Patients treated with TNF-blocker medications (infliximab, adalimumab, etanercept, certolizumab pegol, golimumab, or their biosimilars).
• Safety or Mechanistic Outcomes: Studies that report on infections and/or malignancies as outcomes OR provide mechanistic insights, biological pathways, or explanatory frameworks for TNF-blocker associated adverse events.
• Study Design: Randomized controlled trial, cohort study, case-control study, systematic review, or meta-analysis.
• Adult Population: Including adult patients (≥18 years of age).
• Clinical Indication: TNF-blockers in the study used for treating immune-mediated inflammatory diseases.
• TNF-Specific Focus: Focus on TNF-blockers or comparison data.
• Adequate Sample Size: Minimum of 5 patients for case reports or series.
• Original Human Clinical Data: Reporting original human clinical data.

Data Extraction

We requested data extraction for various categories, including:

• TNF-Blocker Details: Agent(s), dosage, duration, administration route, and combination/monotherapy.
• Patient Population: Treatment indications, sample sizes, demographics, disease history, and risk factors.
• Infection Outcomes: Types of infections, incidence rates, and risk estimates.
• Malignancy Outcomes: Types of malignancies, incidence rates, risk estimates, and relationship to treatment.
• Mechanistic Insights: Biological mechanisms linking TNF-blockers to infections or malignancies.
• Risk Factors: Modifying factors for risk in infections or malignancies.
• Study Methodology: Design, duration, control characteristics, and bias considerations.

Results

Characteristics of Included Studies

Infection Outcomes

Malignancy Outcomes

Mechanistic Insights

TNF plays a critical role in immune surveillance and host defense, creating a theoretical framework for both infection and malignancy risks with TNF inhibition. Multiple biological pathways have been proposed to explain the observed safety signals.

For infections, TNF-α antagonists suppress inflammatory pathways that are essential for immune defense. The disruption of granuloma formation represents a key mechanism for tuberculosis reactivation, as granulomas are crucial for containing mycobacterial infections. This mechanistic understanding explains why tuberculosis risk is elevated 3- to 4-fold and why TB occurs exclusively with monoclonal antibodies that more completely neutralize TNF, compared to the soluble receptor etanercept which may have different immunologic effects.

The clustering of granulomatous infections within 90 days of infliximab initiation is consistent with reactivation of latent infections, suggesting that TNF-blockade unmasks pre-existing but controlled pathogens rather than solely increasing susceptibility to new infections. This mechanistic insight has important implications for pre-treatment screening protocols.

For malignancies, competing mechanisms have been proposed. TNF may suppress tumor development through induction of apoptosis and suppressive effects on gene expression, suggesting that TNF-blockade could enhance cancer risk. Additionally, TNF serves as a key element of inflammatory responses whose inhibition may increase risk of infection-driven cancers, particularly viral malignancies.

Conversely, uncontrolled inflammation itself may potentiate cancer development, as evidenced by higher lymphoma rates in patients with greater systemic inflammation. TNF’s profound effects on angiogenesis, which is critical for tumor growth and metastasis, suggest that anti-TNF therapy could theoretically reduce cancer risk by suppressing both inflammation and angiogenesis. The observation that corticosteroids appear to reduce lymphoma risk supports this anti-inflammatory mechanism.

When TNF-blockers are combined with other immunosuppressants, synergistic immunosuppression may increase both infection and malignancy risks. This is particularly evident for non-melanoma skin cancers, where the combination of TNF-blockers with methotrexate nearly doubled the risk compared to TNF-blockers alone.

Risk Factors and Population Heterogeneity

Several patient and treatment characteristics modified infection and malignancy risk. Older age emerged as a risk factor for infections, though one meta-regression found no significant age association. Comorbid conditions including malnutrition and diabetes increased infection susceptibility.

Concomitant immunosuppressive therapy represented an important modifier, with evidence of synergistic effects when combining TNF-blockers with other systemic immunosuppressants. In psoriatic arthritis trials, 44.6% of patients received concomitant methotrexate, 5.5% other disease-modifying drugs, and 10.5% corticosteroids, while psoriasis trials generally excluded such combinations.

Disease-specific factors showed variable effects. For infections, Crohn’s disease patients demonstrated higher opportunistic infection risk compared to ulcerative colitis. The gastrointestinal system was the most frequent site of serious infections, potentially reflecting the intestinal inflammation in IBD populations. For malignancies, higher systemic inflammation levels increased lymphoma risk independent of treatment, introducing confounding by indication where sicker patients both receive TNF-blockers and have elevated baseline cancer risk.

Treatment-related factors included dose-dependent relationships for malignancies and duration-dependent increases in infection risk. However, longer TNF-blocker exposure did not increase malignancy risk in observational cohorts. Patients with previous malignancies had higher recurrence risk that was not further increased by TNF-blocker exposure, suggesting that baseline cancer risk may be more important than treatment effects in this subgroup.

Agent-specific differences were notable. Infliximab carried 3.25-fold greater granulomatous infection risk than etanercept, with tuberculosis occurring exclusively with monoclonal antibodies. This suggests that complete TNF neutralization by monoclonal antibodies may have different immunologic consequences than the partial blockade achieved by the soluble receptor etanercept.

Synthesis

The systematic review data reveal a complex safety profile for TNF-blockers that cannot be reduced to simple risk estimates. The apparent contradictions in findings—particularly for serious infections and malignancies—can be reconciled by considering methodological factors, population characteristics, and temporal dynamics.

For serious infections, the divergence between meta-analyses finding increased risk (OR 1.25-2.0) and those finding no increase or even protective effects (OR 0.56 in low-bias studies) reflects differences in study quality and outcome ascertainment. The protective finding in low-bias studies is paradoxical and likely represents residual confounding, where healthier patients both tolerate biologics better and have fewer baseline infection risks. Importantly, when infection rates are adjusted for differential follow-up time using incidence rate ratios rather than odds ratios, the association with any infection becomes non-significant (IRR 1.01), suggesting that the modest OR of 1.18-1.20 may partially reflect surveillance bias where treated patients have more clinical encounters and thus more infection detection opportunities.

The consistent signal for opportunistic infections (OR 1.90) and tuberculosis (OR 3.3-3.5) represents a mechanistically plausible effect. These findings are biologically coherent with TNF’s role in granuloma formation and align with the observation that 72% of infliximab-associated infections occur within 90 days, consistent with reactivation of latent infections rather than de novo acquisition. The exclusive occurrence of tuberculosis with monoclonal antibodies but not etanercept further supports a mechanistic relationship, as complete TNF neutralization disrupts granuloma maintenance more profoundly than partial receptor blockade.

For malignancies, the heterogeneity is even more pronounced, with estimates ranging from protective (OR 0.90-0.95) to substantially increased (OR 3.3). This variance can be explained by multiple factors:

• Study Duration and Latency: The meta-analysis by Bongartz et al. finding OR 3.3 included only trials of 12 weeks or longer, representing short-term exposure inadequate to capture cancer development’s slow natural history. Observational studies with longer follow-up found no overall increased risk, and importantly, no evidence that longer exposure increased risk. This temporal pattern suggests that any short-term signal may reflect detection bias or unmasking of pre-existing cancers rather than carcinogenesis.
• Malignancy Type Specificity: The heterogeneity resolves when examining specific cancer types. Skin cancers show consistent increases (OR 1.45 for NMSC), particularly when TNF-blockers are combined with methotrexate (RR 1.97). This likely reflects both immunosuppression-mediated reduction in skin cancer surveillance and the high baseline skin cancer rates in these populations. For lymphomas, observational studies in RA found standardized incidence ratios ranging from 1.8 to 6.0, while a meta-analysis of registries found no significant increase (OR 1.11).
• Population-Specific Baseline Risk: The 1.0% malignancy rate in IBD patients with no significant association in 10 of 11 studies contrasts with findings in RA, where systemic inflammation itself increases lymphoma risk. This suggests that population-specific confounding by indication—where more severe disease necessitates TNF-blockers and independently increases cancer risk—may account for observed associations in some conditions but not others.
• Dose-Response Relationships: The dose-dependent malignancy risk observed in the Bongartz meta-analysis provides mechanistic support for a causal relationship. However, this finding requires reconciliation with the absence of duration-dependent risk in observational cohorts. One explanation is that higher doses may unmask pre-existing cancers more rapidly without increasing cumulative carcinogenesis.
• Agent-Specific Effects: The 3.25-fold greater granulomatous infection risk with infliximab versus etanercept demonstrates that not all TNF-blockers carry equivalent risks. This mechanistic heterogeneity—related to complete versus partial TNF neutralization—means that class-wide safety estimates may obscure important agent-specific differences.

In summary, TNF-blockers demonstrate a mechanistically coherent increased risk of opportunistic infections, particularly tuberculosis reactivation, that appears to be agent-specific and related to granuloma disruption. For malignancies, the preponderance of evidence from longer-term observational studies suggests no overall increased risk, though skin cancers may be modestly increased, particularly with combination immunosuppression. Short-term RCT signals likely reflect detection bias and insufficient latency periods for cancer development. Clinicians should focus on pre-treatment tuberculosis screening and skin cancer surveillance while recognizing that baseline disease severity and inflammation may be stronger cancer predictors than TNF-blocker exposure itself.

References

• Sean M. McConachie, S. Wilhelm, A. Bhargava, P. Kale-Pradhan (2018). Biologic-Induced Infections in Inflammatory Bowel Disease: The TNF-α Antagonists. The Annals of Pharmacotherapy
• R. Pereira, Raquel Faria, P. Lago, T. Torres (2017). Infection and Malignancy Risk in Patients Treated with TNF Inhibitors for Immune-Mediated Inflammatory Diseases. Current Drug Safety
• T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson, and 1 more (2006). Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Journal of the American Medical Association (JAMA)
• X. Mariette, M. Matucci-Cerinic, K. Pavelka, P. Taylor, R. V. van Vollenhoven, and 5 more (2011). Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Annals of the Rheumatic Diseases
• E. Dommasch, K. Abuabara, D. Shin, Josephine C. Nguyen, A. Troxel, and 1 more (2011). The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. Journal of American Academy of Dermatology
• D. Solomon, E. Mercer, A. Kavanaugh (2012). Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis & Rheumatism
• S. Minozzi, S. Bonovas, T. Lytras, V. Pecoraro, Marien González-Lorenzo, and 12 more (2016). Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opinion on Drug Safety
• S. Bonovas, G. Fiorino, M. Allocca, T. Lytras, G. Nikolopoulos, and 2 more (2016). Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clinical Gastroenterology and Hepatology
• R. Wallis, M. Broder, J. Y. Wong, M. Hanson, D. Beenhouwer (2004). Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical Infectious Diseases
• M. Muller, F. D'amico, S. Bonovas, S. Danese, L. Peyrin-Biroulet (2020). TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review. Journal of Crohn's & Colitis